La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Sutro Biopharma Croissance future

Future contrôle des critères 2/6

Sutro Biopharma devrait augmenter ses bénéfices et ses revenus de 2.8% et de 24% par an respectivement, tandis que le BPA devrait croître de croître de 12.1% par an.

Informations clés

2.8%

Taux de croissance des bénéfices

12.1%

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.4%
Taux de croissance des recettes	24.0%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Good
Dernière mise à jour	16 Sep 2024

Mises à jour récentes de la croissance future

Analysts Are Upgrading Sutro Biopharma, Inc. (NASDAQ:STRO) After Its Latest Results

Aug 16

Recent updates

Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology

Sep 23

There's No Escaping Sutro Biopharma, Inc.'s (NASDAQ:STRO) Muted Revenues Despite A 29% Share Price Rise

Aug 24

Brokers Are Upgrading Their Views On Sutro Biopharma, Inc. (NASDAQ:STRO) With These New Forecasts

Aug 22

Analysts Are Upgrading Sutro Biopharma, Inc. (NASDAQ:STRO) After Its Latest Results

Aug 16

The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet As Shares Tumble 28%

Jun 26

We Think The Compensation For Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Looks About Right

May 31

Bearish: Analysts Just Cut Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue and EPS estimates

Apr 02

The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet

Mar 28

Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 43%

Dec 19

Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?

Aug 24

Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?

Feb 10

An Intrinsic Calculation For Sutro Biopharma, Inc. (NASDAQ:STRO) Suggests It's 47% Undervalued

Jan 12

Sutro Biopharma: Partnership Progress Warrants Exposure

Aug 16

New Forecasts: Here's What Analysts Think The Future Holds For Sutro Biopharma, Inc. (NASDAQ:STRO)

Aug 11

Sutro Biopharma GAAP EPS of -$0.55, revenue of $28.1M

Aug 08

Sutro to get $10M payment from Merck after first patient dosed in collaboration trial

Jul 26

Industry Analysts Just Made A Sizeable Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue Forecasts

May 09

Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?

May 07

Sutro Biopharma EPS misses by $0.04, beats on revenue

May 07

Prévisions de croissance des bénéfices et des revenus

NasdaqGM:STRO - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	66	-290	-177	-256	9
12/31/2025	58	-280	-219	-238	11
12/31/2024	69	-228	-187	-171	11
6/30/2024	169	-124	-78	-75	N/A
3/31/2024	154	-115	-119	-115	N/A
12/31/2023	154	-107	-116	-112	N/A
9/30/2023	49	-172	-156	-150	N/A
6/30/2023	57	-143	-57	-50	N/A
3/31/2023	75	-130	-29	-22	N/A
12/31/2022	68	-119	-4	4	N/A
9/30/2022	70	-123	-1	6	N/A
6/30/2022	53	-134	-96	-84	N/A
3/31/2022	53	-114	-101	-87	N/A
12/31/2021	62	-106	-97	-82	N/A
9/30/2021	60	-127	-93	-79	N/A
6/30/2021	69	-79	-85	-72	N/A
3/31/2021	50	-43	-88	-79	N/A
12/31/2020	43	-32	-75	-68	N/A
9/30/2020	46	13	-70	-62	N/A
6/30/2020	40	-17	-66	-61	N/A
3/31/2020	41	-61	-68	-64	N/A
12/31/2019	43	-56	-69	-65	N/A
9/30/2019	51	-42	-60	-58	N/A
6/30/2019	46	-40	4	6	N/A
3/31/2019	41	-38	6	8	N/A
12/31/2018	38	-35	11	13	N/A
9/30/2018	23	-49	12	14	N/A
6/30/2018	33	-40	-38	-36	N/A
3/31/2018	42	-30	N/A	-37	N/A
12/31/2017	52	-20	N/A	-37	N/A
12/31/2016	60	N/A	N/A	-13	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: STRO devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: STRO devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: STRO devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de STRO ( 24% par an) devrait croître plus rapidement que le marché US ( 8.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de STRO ( 24% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de STRO devrait être élevé dans 3 ans

Sutro Biopharma Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Analysts Are Upgrading Sutro Biopharma, Inc. (NASDAQ:STRO) After Its Latest Results

Consensus revenue estimates fall by 16%

Price target decreased by 7.1% to US$12.80

Price target decreased by 12% to US$12.89

Consensus revenue estimates fall by 28%

Price target decreased by 13% to US$14.67

Recent updates

Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO2024

There's No Escaping Sutro Biopharma, Inc.'s (NASDAQ:STRO) Muted Revenues Despite A 29% Share Price Rise

Brokers Are Upgrading Their Views On Sutro Biopharma, Inc. (NASDAQ:STRO) With These New Forecasts

Sutro Biopharma Announces Initiation of REFRaME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer

Analysts Are Upgrading Sutro Biopharma, Inc. (NASDAQ:STRO) After Its Latest Results

Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer

The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet As Shares Tumble 28%

We Think The Compensation For Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Looks About Right

Consensus revenue estimates fall by 16%

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 7.1% to US$12.80

Sutro Biopharma, Inc. Announces Initiation of Randomized Portion (Part 2) of REFRaME-O1 Trial

Sutro Biopharma, Inc., Annual General Meeting, Jun 06, 2024

Price target decreased by 12% to US$12.89

Sutro Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $74.999998 million.

Bearish: Analysts Just Cut Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue and EPS estimates

Sutro Biopharma, Inc. has filed a Follow-on Equity Offering in the amount of $74.999998 million.

Consensus revenue estimates fall by 28%

The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Chief Medical Officer exercised options and sold US$64k worth of stock

Insider notifies of intention to sell stock

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRa-Targeting ADC

Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 43%

Price target decreased by 13% to US$14.67

Sutro Biopharma, Inc. Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

Sutro Biopharma, Inc Appoints Jane Chung as President and Chief Operating Officer

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers At ESMO 2023

Price target decreased by 9.9% to US$16.89

Sutro Biopharma, Inc. Appoints Hans Peter Gerber as Chief Scientific Officer

Chief Business Officer recently sold US$53k worth of stock

Chief Business Officer notifies of intention to sell stock

Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates increase by 10%

Price target decreased by 8.6% to US$17.71

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 7.1% to US$19.75

Full year 2022 earnings: EPS exceeds analyst expectations

CEO & Director exercised options and sold US$100k worth of stock

CFO & Secretary exercised options to buy US$284k worth of stock.

Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?

An Intrinsic Calculation For Sutro Biopharma, Inc. (NASDAQ:STRO) Suggests It's 47% Undervalued

Sutro Biopharma, Inc. Announces Results from Phase 1 Dose-Expansion Study of STRO-002

Sutro Biopharma, Inc. Announces Presentation of STRO-002 Data from the Compassionate Use Program in Pediatric Patients with Relapsed/Refractory CBF/GLIS AML at ASH 2022

Consensus revenue estimates fall by 18%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Sutro Biopharma, Inc. Announces Departure of Arturo Molina as Chief Medical Officer

Price target decreased to US$24.63

Sutro Biopharma: Partnership Progress Warrants Exposure

Consensus revenue estimates increase by 51%

New Forecasts: Here's What Analysts Think The Future Holds For Sutro Biopharma, Inc. (NASDAQ:STRO)

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Sutro Biopharma GAAP EPS of -$0.55, revenue of $28.1M

High number of new directors

Sutro to get $10M payment from Merck after first patient dosed in collaboration trial

Consensus revenue estimates increase by 24%

Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from Russell 2000 Growth Index

High number of new directors

Price target decreased to US$26.75

Consensus revenue estimates fall by 14%

Price target decreased to US$28.63

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?

Sutro Biopharma, Inc., Annual General Meeting, Jun 06, 2022

Sutro Biopharma, Inc. Presents Nonclinical Data for Antibody-Drug Conjugate STRO-002 at the AACR Annual Meeting 2022